If a new rumor is to be believed, then the long delay of the Apple (NASDAQ:AAPL) iWatch is due to the Cupertino electronics company seeking FDA certification of the wearable as a medical device. As reported by G4Games, which traces the rumor back to Chinese reporters who cite anonymous “Apple insiders,” the iWatch’s exact release is still uncertain due to Apple (AAPL) waiting on the United States Food and Drug Administration, whose lengthy testing is frequently complained about but has prevented such problems as thalidomide use in the U.S.
If the iWatch has indeed been submitted for FDA approval, this fact would likewise explain why Apple is even more silent than usual about its new form factor. Until the certification is actually granted, the iWatch’s future is somewhat in doubt, even if the odds favor its successful transition from lab to consumer sales. Apple (AAPL), based around a canny, worldly-wise corporate culture, would not risk an announcement that could later be proven totally false.
The smartwatch seems likely to be linked directly to the Mayo Clinic and other top American medical facilities, as coding in iOS 8 indicates. The iWatch will probably include at least four biometric sensors, measuring heart rate, blood glucose, blood pressure, and perspiration chemistry. The “sweat analysis” function seems to be proprietary to Apple (AAPL), and would be used during exercise to warn of impending dehydration (or, in rare cases, excessive water use).
The latest rumor also seems to solve the “mystery” of why Apple spent the first few months of the year hiring experts in medicine. Hiring such people is a prudent move if FDA certification is indeed being sought, since the medical aspects of the iWatch would need to be designed to the highest current medical standards to quickly pass the certification process and reach store shelves on schedule.